InspireMD Inc ((NSPR)) has held its Q3 earnings call. Read on for the main highlights of the call.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
InspireMD Inc’s recent earnings call painted a picture of robust growth and promising prospects, despite some financial hurdles. The sentiment was largely positive, with significant revenue growth attributed to the successful U.S. launch of CGuard Prime and strong international performance. While the company faced increased operating expenses and a higher net loss, these challenges were overshadowed by the positive achievements and growth outlook.
Significant Revenue Growth
InspireMD reported a total revenue of $2.5 million for the third quarter of 2025, marking a 39% increase year-over-year and over 40% sequential growth. This impressive growth underscores the company’s successful strategies and market penetration.
Successful Launch of CGuard Prime in the U.S.
The third quarter marked the first instance of U.S. commercial revenue for InspireMD, with $497,000 generated following the FDA approval of CGuard Prime in June 2025. This launch represents a significant milestone for the company in the U.S. market.
Strong International Performance
International revenue reached $2.0 million, a 12% increase compared to the same period last year. This growth was driven by increased product usage across more than 30 markets and favorable foreign exchange impacts.
Gross Margin Improvement
InspireMD achieved a gross profit increase of over 100% to $864,000, with gross margins rising to 34.2% from 22.9% the previous year. This improvement highlights the company’s effective cost management and operational efficiency.
Strong Financial Position
The company’s financial position was bolstered by successful financing events, raising a total of $58 million. As of September 30, 2025, cash and cash equivalents stood at $63.4 million, providing a solid foundation for future growth.
Expansion of Clinical Trials
InspireMD is making strides in clinical trials, with progress in C-GUARDIANS II and III. The expected FDA clearance and launches in mid-2026 and mid-2027, respectively, demonstrate the platform’s versatility and clinical value.
Appointment of New Chief Medical Officer
Dr. Peter Soukas has been appointed as the new Chief Medical Officer, tasked with overseeing clinical and medical topics. His appointment is expected to enhance the company’s clinical excellence and market awareness.
Increase in Operating Expenses
Operating expenses rose to $13.9 million, a 57% increase from the previous year, primarily due to higher headcount-related expenses and infrastructure costs. This increase reflects the company’s investment in growth and expansion.
Net Loss Increase
The net loss for the third quarter was $12.7 million, up from $7.9 million in the same period in 2024. This increase is attributed to the rise in operating expenses and other financial challenges.
Decrease in Financial Income
Financial income decreased by $229,000, mainly due to reduced income from investments and increased financial expenses related to exchange rate changes.
Forward-Looking Guidance
Looking ahead, InspireMD anticipates fourth-quarter revenue between $2.5 million and $3.0 million. The company expects continuous growth from U.S. sales and consistent international demand, supported by the strong initial launch of CGuard Prime and steady international performance.
In summary, InspireMD’s earnings call highlighted a positive outlook with significant revenue growth and strategic advancements. Despite facing financial challenges, the company’s successful product launches and international expansion provide a strong foundation for future growth.